Previous Close | 1,960.00 |
Open | 0.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 0.00 - 0.00 |
52 Week Range | |
Volume | |
Avg. Volume | 619,927 |
Market Cap | 4.34B |
Beta (5Y Monthly) | 0.44 |
PE Ratio (TTM) | 28.76 |
EPS (TTM) | 0.68 |
Earnings Date | Feb 22, 2024 |
Forward Dividend & Yield | 0.57 (2.93%) |
Ex-Dividend Date | Mar 21, 2024 |
1y Target Est | 26.01 |
Key Insights Significantly high institutional ownership implies Hikma Pharmaceuticals' stock price is sensitive to...
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
Merck has received a letter that Hikma Pharmaceuticals US unit has sought a pre-patent expiry approval from the US FDA to sell a generic version of its Bridion injection, the drugmaker said in filing on Monday. Merck said, on Feb. 5, it received the letter under the Hatch-Waxman Act, through which a company can seek FDA approval to market a copycat before the expiration of patents related to the brand-name drug. Merck said in the filing that it is currently considering its options.